Harith Rajagopalan Sells 96,517 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 96,517 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. The trade was a 16.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Fractyl Health Stock Performance

Fractyl Health stock opened at $2.09 on Friday. Fractyl Health, Inc. has a 52-week low of $1.74 and a 52-week high of $14.50. The company has a quick ratio of 7.46, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average is $2.61 and its 200 day moving average is $4.04.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. As a group, equities research analysts predict that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

A number of large investors have recently made changes to their positions in GUTS. BNP Paribas Financial Markets boosted its position in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after buying an additional 7,397 shares during the period. Rhumbline Advisers bought a new position in Fractyl Health during the 2nd quarter worth about $32,000. SG Americas Securities LLC purchased a new position in Fractyl Health during the 3rd quarter valued at about $33,000. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health in the 2nd quarter worth approximately $61,000. Finally, Beta Wealth Group Inc. purchased a new position in Fractyl Health during the third quarter valued at approximately $44,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.